Profitelligence Profitelligence · Filing Ledger Open GILD research →

Form 8-K · Current Report · Filed 2026-02-23

Gilead Sciences to Acquire Arcellx for $7.8 Billion

Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx, Inc. for a total value of $7.8 billion, payable at closing. The transaction includes $115 per share in cash and one contingent value right of $5 per share, contingent upon the achievement of certain sales milestones. The acquisition aims to accelerate the development and commercialization of Arcellx's anito-cel, an investigational CAR T-cell therapy for multiple myeloma. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including regulatory approvals.

Filer
Gilead Sciences Inc. GILD · NASDAQ
Filed
Accession
0001104659-26-018314
CIK
0000882095
Signal
High impactHealthcare

Items reported

Item events

Reported Item

M&A Agreement Strategic Partnership CFO Resignation

Market reaction

Close before filing

$151.40

Next session

-2.5%

Since filing

-14.0%

Latest close

$130.21

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from GILD reporting the same item, with the next session's move:

About Gilead Sciences Inc.

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.

Exchange NASDAQ Industry Drug Manufacturers - General Company website ↗

Never miss another GILD filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts